Flagship Harbor Advisors LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) ...

The outlook for Wilmington, Massachusetts-based contract research organization (CRO) Charles River Laboratories International ...

Fifth Third Bancorp cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by ...

BofA lowered the firm’s price target on Charles River (CRL) to $195 from $210 and keeps a Neutral rating on the shares. The firm updated its ...

Bank of America Securities analyst Juan Avendano reiterated a Hold rating on Charles River Labs (CRL – Research Report) today and set a price ...

Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...